BRCA1 and BRCA2 gene mutation testing, as well as their correlation with higher Gleason scores (8>), and therapeutic use in PCa management, have drawn the attention of experts to familial PCa in particular (Amsi et al., 2020). Here, BRCA2 is linked to posterior cortical atrophy.